Sandoz enters agreement to expand sales of Veregen ointment

PRINCETON, N.J. — Sandoz, through its branded dermatology business PharmaDerm, and Medigene AG on Thursday announced a promotion agreement with Women's Choice Pharmaceuticals for Veregen (sinecatechins) ointment, 15% strength. 

 

The topical ointment is used for the treatment of external genital or perianal warts in inmmunocompetent patients ages 18 years and older. The goal of the agreement is to expand product sales into the obstetrics, gynecology and urology fields in the United States through increased physician coverage, the company stated. 

 

"Veregen is an important part of our PharmaDerm’s portfolio of branded products,” said Peter Goldschmidt, president of Sandoz. “By expanding physician promotion to key clinically relevant physicians, we can increase awareness about this important treatment option.”